Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 1—January 2024
Research

Racial and Ethnic Disparities in Tuberculosis Incidence, Arkansas, USA, 2010–2021

On This Page
Methods
Results
Discussion
Cite This Article
Tables
Table 1
Table 2
Table 3
Table 4
Table 5
Table 6
Downloads
Article
Appendix
RIS [TXT - 2 KB]
Article Metrics
Metric Details
Related Articles
Detecting Subclinical Tuberculosis, Peru
Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017–2022
Prioritizing Mental Health in PEPFAR
More articles on Tuberculosis
Author affiliations: University of Michigan, Ann Arbor, Michigan, USA (M. Humayun, W. Ye, Z. Yang); Arkansas Department of Health, Little Rock, Arkansas, USA (L. Mukasa, J.H. Bates); University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA (L. Mukasa, J.H. Bates)

Cite This Article

Abstract

We conducted an epidemiologic assessment of disease distribution by race/ethnicity to identify subpopulation-specific drivers of tuberculosis (TB). We used detailed racial/ethnic categorizations for the 932 TB cases diagnosed in Arkansas, USA, during 2010–2021. After adjusting for age and sex, racial/ethnic disparities persisted; the Native Hawaiian/Pacific Islander (NHPI) group had the highest risk for TB (risk ratio 173.6, 95% CI 140.6–214.2) compared with the non-Hispanic White group, followed by Asian, Hispanic, and non-Hispanic Black. Notable racial/ethnic disparities existed across all age groups; NHPI persons 0–14 years of age were at a particularly increased risk for TB (risk ratio 888, 95% CI 403–1,962). The risks for sputum smear–positive pulmonary TB and extrapulmonary TB were both significantly higher for racial/ethnic minority groups. Our findings suggest that TB control in Arkansas can benefit from a targeted focus on subpopulations at increased risk for TB.

Globally, tuberculosis (TB) is the 13th leading cause of death and a leading infectious killer, second to COVID-19 (1,2). In 2021, TB affected 10.6 million persons and caused 1.6 million deaths worldwide (2). Moreover, a quarter of the world’s population is latently infected with Mycobacterium tuberculosis, which puts them at a 5%–10% lifetime risk of developing active disease (2–4). Global trends indicate that the World Health Organization’s (WHO) End TB Strategy milestones will likely be missed because TB incidence has reduced by only 10% and TB deaths by 5.9% during 2015–2021, compared with the desired goals of 20% reduction in incidence and 35% reduction in deaths (2,5). The COVID-19 pandemic has further disrupted TB notification and treatment, reversing the progress toward global TB elimination while widening existing inequalities (2,6).

The TB epidemic is considered a major challenge in low-resource, high-burden countries; 30 high-burden countries represent 87% of the global burden (2). However, the epidemiology of TB in low-incidence countries is characterized by concentration of the TB burden, sometimes as high as in high-burden countries, among socially and historically marginalized populations (7,8). Before the impact of COVID-19 on TB notification, TB incidence continued to decline during 1993–2019 in the United States; however, the annual rate at which TB declined plateaued during the later years (9). Similarly, a recent study from Arkansas reported no significant decline in TB incidence during 2009–2020 (10). To move toward preelimination (1 case/100,000 population) and eventually elimination (<1 case/100,000 population), current TB interventions should be adapted to unique local challenges focusing on populations at increased risk for TB as suggested by WHO’s action framework for TB elimination in low-incidence countries (7,8). This framework calls for epidemiologic assessment of disease distribution in the local population by important sociodemographic variables; however, such disaggregated analysis is typically not available in TB surveillance reports, limiting the ability of public health programs to develop pro-equity policies (7,8,11,12).

In the United States, race is a strong social determinant of health because it serves as a proxy for systemic and structural barriers to equitable opportunities for education, employment, earning, housing, and healthcare, which perpetuates racial discrimination and unjust distribution of resources that lead to adverse health outcomes (13,14). In this study from Arkansas, USA, a state with TB incidence below the national average of 2.4 cases/100,000 population, we quantify the racial/ethnic disparities in TB incidence at the population level using detailed racial/ethnic categorizations that have not been widely used in previous TB studies in Arkansas (15–17). This study will not only help map subpopulations at an increased risk for TB in a low-burden setting but also guide the development of targeted TB interventions in light of the underlying factors that differentially drive TB incidence across racial/ethnic groups.

This study used de-identified patient data that we retrospectively retrieved from the TB surveillance database maintained by the Arkansas Health Department. The University of Michigan Health Sciences and Behavioral Sciences Institutional Review Board (IRB-HSBS) determined that this study was not regulated.

Methods

Study Population

This study included all 932 TB cases diagnosed in Arkansas during 2010–2021. All of these cases met the Centers for Disease Control and Prevention (CDC)’s definition of a verified TB case. These verified cases met either laboratory or clinical case definition, including those verified by provider diagnosis as described in CDC’s TB case reporting manual (18).

Data Collection and Data Sources

Demographic and clinical data available in this dataset were collected on verified TB cases using the standard CDC TB reporting form. We obtained US Census Bureau official population estimates for 2010–2019 from annual resident population estimates for 6 race groups (5 race-alone groups and 2 or more races) by age, sex and Hispanic origin for states and the District of Columbia from April 1, 2010–July 1, 2019; April 1, 2020; and July 1, 2020. We obtained population estimates for 2020 and 2021 from annual state resident population estimates for 6 race groups (5 race-alone groups and 2 or more races) by age, sex, and Hispanic origin from April 1, 2020–July 1, 2021 (19).

Data Analysis

This study had 4 objectives. The objectives were to characterize racial/ethnic disparities in TB risk; to determine if the observed racial/ethnic disparities were a result of underlying differences in sex and age distribution; to track age-specific incidence for racial/ethnic groups to draw inferences related to the underlying drivers of TB incidence; and to characterize racial/ethnic differences in advanced TB disease at diagnosis.

From the TB surveillance dataset, we created a combined variable for race and ethnicity with 5 categories so that we did not consider racial/ethnic identities in isolation (20). The Hispanic category included all racial subcategories. We categorized non-Hispanic persons into Asian, non-Hispanic Black, Native Hawaiian/Pacific Islander (NHPI), and non-Hispanic White categories. We did not include American Indian/Alaska Native (n = 4) and multirace (n = 1) categories in race/ethnicity-stratified results because of their small sample sizes. We categorized age as 0–14 years, 15–24 years, 25–44 years, 45–64 years, and >65 years. Consistent with the definition used by CDC, US-born persons included those who were eligible for US citizenship at the time of birth regardless of place of birth.

To address the first objective, we calculated the overall TB incidence for the period 2010–2021, with corresponding 95% CI for the state and the 5 racial/ethnic groups mentioned. We calculated TB incidence per 100,000 population using the population estimates from the US Census Bureau (19). We estimated TB incidence in the overall population and stratified by race/ethnicity and age group using Poisson regression with an offset term for the total population size. To further characterize TB-related disparities, we calculated risk ratio (RR) estimates for the race/ethnicity-combined variable, sex, and age group using Poisson regression. Because age and sex are important determinants of TB risk, we calculated race/ethnicity RRs that were adjusted for both age and sex concurrently using Poisson regression to achieve our second objective. In the absence of genotyping data, age-specific TB incidence can help draw inferences related to the underlying mechanisms that drive TB incidence. Previous studies demonstrated that TB among older adults strongly reflects reactivation of latent TB infection (LTBI) in low-burden settings, whereas TB is typically a result of recent transmission among young children (21,22). Hence, the third objective determined how racial disparities tracked across age groups by reporting RRs for race/ethnicity from age-specific Poisson models adjusted for sex. In addition, to track age disparities within each racial/ethnic group, we reported RRs for age groups from race/ethnicity-specific Poisson models while adjusting for sex.

Pulmonary TB (PTB) often starts with minimum infiltrate and progresses to additional infiltrate; sputum smear positivity has been used previously as a proxy for delayed diagnosis (17). The occurrence of extrapulmonary TB (EPTB) often reflects the spread of M. tuberculosis outside of the lungs due to the host’s inability to contain the infection (23). We evaluated sputum smear–positive PTB and EPTB as important indicators for advanced disease. For those 2 outcomes, we calculated RRs and adjusted RRs for the race/ethnicity-combined variable, sex, and age group using Poisson regression.

We used the non-Hispanic White category as the reference group for race/ethnicity and female as the reference category for sex because those groups were at the lowest risk for TB compared with other variable categories. For age, no one category was at the lowest risk for TB across stratified results, so we used the >65 years age category as the reference group to follow how TB risk progressed with age. We determined model fit using a goodness-of-fit test. We conducted statistical analysis using the SAS OnDemand for Academics (SAS Institute Inc., https://www.sas.com).

Results

Characteristics of Study Sample

Among the 932 TB cases in our study, 72% were bacteriologically confirmed through either nucleic acid amplification test or positive culture (Table 1). Most TB cases (76.5%) were exclusively diagnosed as PTB patients. Among all TB patients, 35.73% had a positive sputum smear result and 43.2% of the patients with PTB diagnosis (including those with both PTB and EPTB) had a positive sputum smear result. Of the total study sample, 86.6% of TB patients identified as non-Hispanic with diverse racial categorizations; 63.2% of the study patients were male. Most case-patients among Asian (91.7%), NHPI (67.4%), and Hispanic (82.4%) persons were not US born, and all of the non–US-born NHPI TB case-patients in this study were born in the Marshall Islands. For the non-Hispanic White group, only 2.3% of TB cases were non–US born, and for the non-Hispanic Black group, only 6.1% of TB cases were non–US born.

Racial/Ethnic Disparity in TB Incidence

The overall TB incidence in Arkansas was 2.6 (95% CI 2.4–2.8) cases/100,000 population during 2010–2021 (Table 2). Upon stratifying by race/ethnicity, the NHPI persons (131.6 [95% CI 111.4–155.5] cases/100,000 population) had the highest incidence of TB followed by Asian (20.0 [95% CI 16.6–24.2] cases/100,000 population), Hispanic (4.8 [95% CI 4.0– 5.7] cases/100,000 population), non-Hispanic Black (4.4 [95% CI 3.9–5.0] cases/100,000 population), and non-Hispanic White persons (1.2 [95% CI 1.0–1.3] cases/100,000 population).

Racial/Ethnic Disparity after Adjusting for Sex and Age Differences

Based on the unadjusted model (Table 3), the risk for TB was many folds higher for all racial/ethnic groups when compared with the non-Hispanic White group. The risk for TB for NHPI persons was 113 (95% CI 92.1–137.7) times the risk for non-Hispanic White persons. Asian (RR 17.1, 95% CI 13.8–21.3) Hispanic (RR 4.0, 95% CI 3.3–5.0), and non-Hispanic Black (RR 3.8, 95% CI 3.2–4.5) persons all had higher risk for TB than non-Hispanic White persons. Male persons were at an 81% (RR 1.8, 95% CI 1.6–2.1) higher risk for TB than female persons. The risk for TB was 66% (RR 0.3, 95% CI 0.3–0.4) lower for the youngest group, 0–14 years of age, compared to the oldest age group. TB risk increased with age; the >65-year age group had the highest risk for TB.

After adjusting for age group and sex, racial/ethnic disparities continued to persist. NHPI persons were at the highest risk for TB compared with non-Hispanic White persons (RR 173.6, 95% CI 140.6– 214.2), followed by Asian (RR 21.6, 95% CI 17.3– 27.0), Hispanic (RR 5.9, 95% CI 4.8– 7.4), and non-Hispanic Black (RR 4.6, 95% CI 3.9–5.5) persons.

Age-Related Racial/Ethnic Disparities in TB Incidence

The statewide TB incidence was highest among the >65-year age group (3.8 [95% CI 3.3– 4.3] cases/100,000 population) whereas the youngest group, 0–14 years, had the lowest incidence (1.3 [95% CI 1.1–1.6] cases/100,000 population). Risk for TB increased with age in Arkansas (Table 2). The 0–14-year age group had the lowest risk for TB compared with the ≥65 year age group for non-Hispanic White (RR 0.05, 95% CI 0.02– 0.11), non-Hispanic Black (RR 0.18, 95% CI 0.11–0.30), Asian (RR 0.09, 95% CI 0.02–0.42), and Hispanic (RR 0.08, 95% CI 0.04–0.18) groups, (Table 4). We observed no significant age differences for the NHPI group (p = 0.13). NHPI persons 0–14 years of age had 888 (95% CI 403–1,962) times and NHPI persons >65 years of age had 55 (95% CI 20–148) times the risk of TB compared to similarly aged non-Hispanic White persons (Table 5).

Racial/Ethnic Disparity in Advanced Disease at Diagnosis

The risk for sputum smear-positive PTB was highest for NHPI persons (RR 138.8, 95% CI 94.7–203.7), followed by Asian (RR 14.4, 95% CI 9.5–22.0), Hispanic (RR 5.5, 95% CI 3.8–8.0), and non-Hispanic Black (RR 4.8, 95% CI 3.7–6.3) persons when compared with non-Hispanic White persons (Table 6). The risk for EPTB was highest for NHPI persons (RR 133.3, 95% CI 83.7–212.4), followed by Asian (RR 31.4, 95% CI 21.1–46.7), Hispanic (RR 5.3, 95% CI 3.3–8.3), and non-Hispanic Black (RR 4.5, 95% CI 3.1–6.3) persons compared to non-Hispanic White persons (Table 6).

Discussion

The TB incidence in the United States and Arkansas has been <10 cases/100,000 population for several years; however, neither the state nor the country has been able to make the final push toward preelimination and elimination targets. The underlying epidemiologic factors that drive the remaining TB epidemic in low-incidence countries differ from those in high-burden settings and also across subpopulations within low-incidence settings, which suggests the need for locally informed, context-specific TB interventions (24).

Our study provides an in-depth epidemiologic understanding of the concentrated TB epidemic in Arkansas that is not well captured by aggregated statewide estimates. We found remarkable disparities in TB incidence around the axes of race/ethnicity, sex, and age. Of particular importance were racial/ethnic disparities, which could not be explained by age and sex differences across racial/ethnic groups. Age-specific TB incidence and differences in clinical manifestation of TB at diagnosis across racial/ethnic categories hold important lessons for understanding the drivers of TB incidence and challenges related to health equity in Arkansas.

The racial/ethnic disparities that we observed in our study are consistent with previous studies conducted in Arkansas and the United States, which consistently reported racial disparities in risk for LTBI, recent transmission, and TB disease (13,15,16,25,26). In 2021, a total of 88.1% of the TB cases reported in the United States were attributable to racial/ethnic minorities (9,27). Such observed racial disparities can be explained as a consequence of structural racism that perpetuates health inequities primarily through 2 interlinked pathways: residential segregation and inadequate healthcare (14,28). Persons from racial/ethnic minority groups are more likely to live in neighborhoods with high population density, limited healthcare access, poor housing conditions, and greater air pollution, which makes them more susceptible to acquiring TB infection (14,28,29). Moreover, those persons are more likely to experience conditions such as diabetes, HIV, and malnutrition that can contribute toward progression to TB disease (28,30). In essence, race is associated with socioeconomic status (SES), including generational wealth, income, and education, which then mediates the relationship between race and susceptibility to infection and progression to disease through psychosocial stress, nutrition, physical environment, healthcare access, and immune function (28,31).

The NHPI persons in Arkansas had a strikingly high TB incidence of 131.6 cases/100,000 population, many times higher than their annual national-level TB incidence rate that has remained <20 cases/100,000 during 2003–2021 (9,32). Most of the TB case-patients among NHPI in our study were born in the Marshall Islands, where TB incidence was 280.6 cases/100,000 population in 2020 and 343.2 cases/100,000 population in 2021 (9,32). Decades of colonial rule and testing of nuclear weapons by the US government during 1946–1958 had socioeconomic repercussions for the health infrastructure of the Marshall Islands, where the prevalence of comorbidities that substantially increase TB risk is alarmingly high (33). Under the Compact of Free Association, the people of the Marshall Islands can freely travel, live, and work in the United States, where they experience language, cultural, and economic barriers when accessing healthcare that can lead to infection, delayed diagnosis, and prolonged infectiousness with implications for community transmission (34,35). Despite the high incidence of TB in the Marshall Islands, persons from that country are not required to undergo screening for LTBI or active disease upon arrival to the United States (36). Screening those persons for TB may help in early diagnosis and treatment, thereby reducing the burden of TB in Arkansas and among NHPI persons.

TB is driven by various mechanisms, mainly by reactivation of LTBI or primary disease by a recent transmission, each of which requires specialized mitigation strategies (37). TB incidence was 139.6 cases/100,000 population among 0–14-year-old NHPI children in our study; incidence was<2 cases/100,000 population among all other racial/ethnic groups of similar age. The risk among 0–14-year-old NHPI children was 888 times the risk among non-Hispanic White children of similar age. Because progression from infection to disease is rapid, TB among young children is a good marker for ongoing community transmission (38,39). Given the high risk for sputum smear positive PTB and elevated TB risk among 0–14-year-olds, TB transmission appears to play a role in driving TB incidence among NHPI persons. Hence, to curtail the disproportionate TB burden for NHPI persons, mitigation strategies should focus on active case finding in addition to LTBI screening of adults to disrupt chains of transmission (36). Curtailing the TB epidemic will also require ramping up contact tracing based on contact disclosure from TB patients, who often hesitate to name contacts because of stigma around TB in their communities (40). Community-level advocacy and awareness using culturally appropriate tools can improve contact disclosure and equip the local community with the necessary information on TB diagnosis, treatment, and transmission (40).

For Hispanic, non-Hispanic White, and non-Hispanic Black persons, the risk for TB was highest among the oldest age group, indicating that TB is likely driven by reactivation of LTBI in those subpopulations (41). Two previous studies conducted in Arkansas using genotyping data from 1997–2010 demonstrated that TB incidence among >65-year-olds was largely driven by nonclustered TB incidence, which is indicative of reactivation of LTBI (15,16). In addition, foreign-born non-Hispanic White, non-Hispanic Black, Asian, and Hispanic persons had significantly higher risks for TB than did US-born persons (Appendix Table). The high risk among foreign-born persons likely indicates reactivation, as suggested by a previous national-level study based on genotyping data (42). Racial/ethnic groups with a high proportion of foreign-born TB cases can particularly benefit from TB control efforts focused on preventing reactivation of LTBI.

Sputum smear–positive PTB is highly infectious because its high bacillary load leads to an elevated risk for transmission (43,44). In addition, the increased risk of smear-positive PTB at first diagnosis in persons from racial/ethnic minority groups likely points toward differential access to timely and adequate TB care, previously supported by a study from Arkansas, and such difference can result in severe disease with poor health outcomes (17,44). Another study from Arkansas found that TB patients from rural Arkansas faced delays in receiving the correct diagnosis and were treated for other conditions for several months (40). Our findings suggest the need to explore the barriers related to TB care that affect various subpopulations in Arkansas. Increasing awareness of TB among healthcare workers, especially in a time when TB incidence is low in the country can help equip them with the knowledge needed to make timely and accurate TB diagnosis (40).

The increased risk for EPTB, including concurrent PTB, among persons from racial/ethnic minority groups is indicative of elevated risk for advanced disease that is a diagnostic and a therapeutic challenge due to the dissemination of the disease (45). An increased prevalence of comorbidities such as HIV might predispose racial/ethnic minority groups to EPTB, suggesting the need for improved management of risk factors that compromise host immunity (46). The Arkansas Office of Minority Health and Health Disparities reported that among non-Hispanic Black persons, the mortality rate for HIV was 6 times higher and for diabetes was 2 times higher than the rates among non-Hispanic White persons during 2011–2015 (47). TB preventive strategies should go beyond curtailing transmission and focus on improved comanagement of noncommunicable conditions, which are often modifiable risk factors, by collaborating across health programs to provide more holistic patient-centered care (48).

This study relies on surveillance data that provides access to limited study variables. We used markers of advanced TB disease to make inferences related to access to timely and adequate care in Arkansas. To clarify the factors that limit access to timely care, future studies should collect qualitative data crucial for determining delays in healthcare and assessing if these delays are patient- or provider-related to bridge health inequities related to TB care. Distinguishing between ongoing community transmission and reactivation of remotely acquired TB infection is crucial when designing TB interventions, but lack of genotyping data in this study prevented reliable evaluation of the relative contribution of each of these 2 mechanisms across racial/ethnic groups (49). Despite those limitations, this study provides incidence and RR estimates stratified by detailed racial/ethnic categories that had not been previously reported at the population level for Arkansas using the most recent surveillance data (11,15–17).

The state-level estimates of TB incidence in Arkansas are misleading because the progress toward TB elimination is unequally felt across racial/ethnic subpopulations. Our findings demonstrate that drivers of TB incidence vary across subpopulations, which necessitates designing context-specific TB interventions. Although our results may not be generalizable to other low-incidence settings, the racial/ethnic disparities we observed demonstrate the need for detailed disaggregated analysis of TB surveillance data by race/ethnicity while providing a framework for such an analysis in other US states.

Ms. Humayun is an PhD candidate in epidemiological science at the University of Michigan, Ann Arbor, Michigan. She received her MPH in epidemiology from University of Maryland as a Fulbright Scholar. Her research interests lie in infectious disease epidemiology, especially global tuberculosis disparities, and TB-HIV coinfection.

Top

Acknowledgments

We thank colleagues in the Tuberculosis Control Program at the Arkansas Health Department for their assistance in the collection of the TB surveillance data used in this study.

The deidentified TB surveillance data used for this study can be shared with other research teams after the review and approval of their research proposal by the Arkansas Department of Health’s Scientific Advisory Committee. The aggregated data and code generated in this study are available upon request to Zhenhua Yang, zhenhua@umich.edu.

Author contributions: M.H. contributed to the study design, data analysis, interpretation of results, and drafting of the manuscript. L.M. contributed to the data collection. W.Y. contributed to the data analysis and development of the manuscript. J.B. contributed to the development of the manuscript and interpretation of the results. Z.Y. contributed to the study design and directed the conduction of the study and the development of the manuscript. All the authors contributed to the revision of the manuscript and approved the final manuscript.

Top

References

  1. World Health Organization. WHO reveals leading causes of death and disability worldwide: 2000–2019. Geneva: The Organization; 2020.
  2. World Health Organization. Global tuberculosis report. TB incidence. 2022 [cited 2023 Nov 28]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-disease-burden/2-1-tb-incidence.
  3. Centers for Disease Control and Prevention. Core curriculum on tuberculosis: what the clinician should know. 7th edition. 2021 [cited 2023 Nov 28]. https://www.cdc.gov/tb/education/corecurr/pdf/CoreCurriculumTB-508.pdf.
  4. Houben  RMGJ, Dodd  PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13:e1002152. DOIPubMedGoogle Scholar
  5. World Health Organization. The End TB strategy. Geneva: The Organization; 2015 [cited 2023 Nov 28]. https://cdn.who.int/media/docs/default-source/documents/tuberculosis/end-tb-brochure22cf78c9-ddf7-47df-9261-b999e8df83ba.pdf
  6. Next steps in eliminating tuberculosis in the Americas. Lancet Reg Heal—Americas 2023;21:100512.
  7. World Health Organization. Towards TB elimination: an action framework for low-incidence countries. 2014 [cited 2023 Nov 28]. https://apps.who.int/iris/bitstream/handle/10665/132231/9789241507707_eng.pdf
  8. Lönnroth  K, Migliori  GB, Abubakar  I, D’Ambrosio  L, de Vries  G, Diel  R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45:928–52. DOIPubMedGoogle Scholar
  9. Filardo  TD, Feng  P-J, Pratt  RH, Price  SF, Self  JL. Tuberculosis - United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:441–6. DOIPubMedGoogle Scholar
  10. Renardy  ME, Gillen  C, Yang  Z, Mukasa  L, Bates  J, Butler  R, et al. Disease phenotypic and geospatial features vary across genetic lineages for Tuberculosis within Arkansas, 2010-2020. PLOS Glob Public Health. 2023;3:e0001580. DOIPubMedGoogle Scholar
  11. Arkansas Department of Health Tuberculosis Control Program. Tuberculosis morbidity annual statistical report 2016. 2016 [cited 2023 Dec 5]. https://www.healthy.arkansas.gov/images/uploads/pdf/2016_Tuberculosis_Statistical_Report_Final.pdf
  12. Heuvelings  CC, de Vries  SG, Grobusch  MP. Tackling TB in low-incidence countries: improving diagnosis and management in vulnerable populations. Int J Infect Dis. 2017;56:77–80. DOIPubMedGoogle Scholar
  13. Noppert  GA, Wilson  ML, Clarke  P, Ye  W, Davidson  P, Yang  Z. Race and nativity are major determinants of tuberculosis in the U.S.: evidence of health disparities in tuberculosis incidence in Michigan, 2004-2012. BMC Public Health. 2017;17:538. DOIPubMedGoogle Scholar
  14. Bailey  ZD, Krieger  N, Agénor  M, Graves  J, Linos  N, Bassett  MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389:1453–63. DOIPubMedGoogle Scholar
  15. Berzkalns  A, Bates  J, Ye  W, Mukasa  L, France  AM, Patil  N, et al. The road to tuberculosis (Mycobacterium tuberculosis) elimination in Arkansas; a re-examination of risk groups. PLoS One. 2014;9:e90664. DOIPubMedGoogle Scholar
  16. France  AM, Cave  MD, Bates  JH, Foxman  B, Chu  T, Yang  Z. What’s driving the decline in tuberculosis in Arkansas? A molecular epidemiologic analysis of tuberculosis trends in a rural, low-incidence population, 1997 2003. Am J Epidemiol. 2007;166:662–71. DOIPubMedGoogle Scholar
  17. Yang  ZH, Gorden  T, Liu  DP, Mukasa  L, Patil  N, Bates  JH. Increasing likelihood of advanced pulmonary tuberculosis at initial diagnosis in a low-incidence US state. Int J Tuberc Lung Dis. 2018;22:628–36. DOIPubMedGoogle Scholar
  18. Centers for Disease Control and Prevention. Report of verified case of tuberculosis, instructional manual. 2020. [cited 2021 Jan 8]. https://www.cdc.gov/tb/programs/rvct/InstructionManual.pdf
  19. US Census Bureau. State population totals and components of change: 2020–2022. 2022 [cited 2022 Feb 12]. https://www.census.gov/data/tables/time-series/demo/popest/2020s-state-total.html
  20. Flanagin  A, Frey  T, Christiansen  SL, Bauchner  H. The reporting of race and ethnicity in medical and science journals. JAMA. 2021;325:1049–52. DOIPubMedGoogle Scholar
  21. Wu  IL, Chitnis  AS, Jaganath  D. A narrative review of tuberculosis in the United States among persons aged 65 years and older. J Clin Tuberc Other Mycobact Dis. 2022;28:100321. DOIPubMedGoogle Scholar
  22. Shingadia  D, Novelli  V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis. 2003;3:624–32. DOIPubMedGoogle Scholar
  23. Baykan  AH, Sayiner  HS, Aydin  E, Koc  M, Inan  I, Erturk  SM. Extrapulmonary tuberculosıs: an old but resurgent problem. Insights Imaging. 2022;13:39. DOIPubMedGoogle Scholar
  24. Houben  RMGJ, Menzies  NA, Sumner  T, Huynh  GH, Arinaminpathy  N, Goldhaber-Fiebert  JD, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health. 2016;4:e806–15. DOIPubMedGoogle Scholar
  25. Kim  S, Cohen  T, Horsburgh  CR Jr, Miller  JW, Hill  AN, Marks  SM, et al. Trends, mechanisms, and racial/ethnic differences of tuberculosis incidence in the US-born population aged 50 years or older in the United States. Clin Infect Dis. 2022;74:1594–603. DOIPubMedGoogle Scholar
  26. Khan  A, Marks  S, Katz  D, Morris  SB, Lambert  L, Magee  E, et al. Changes in tuberculosis disparities at a time of decreasing tuberculosis incidence in the United States, 1994–2016. Am J Public Health. 2018;108(S4):S321–6. DOIPubMedGoogle Scholar
  27. US Centers for Disease Control and Prevention. Health disparities in TB. 2022 [cited 2023 Nov 28]. https://www.cdc.gov/tb/topic/populations/healthdisparities/default.htm
  28. Noppert  GA, Malosh  RE, Moran  EB, Ahuja  SD, Zelner  J. Contemporary social disparities in TB infection and disease in the USA: a review. Curr Epidemiol Rep. 2018;5:442–9. DOIPubMedGoogle Scholar
  29. Mathema  B, Andrews  JR, Cohen  T, Borgdorff  MW, Behr  M, Glynn  JR, et al. Drivers of tuberculosis transmission. J Infect Dis. 2017;216(suppl_6):S644–53. DOIPubMedGoogle Scholar
  30. Lönnroth  K, Jaramillo  E, Williams  BG, Dye  C, Raviglione  M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 2009;68:2240–6. DOIPubMedGoogle Scholar
  31. Noppert  GA, Clarke  P, Hicken  MT, Wilson  ML. Understanding the intersection of race and place: the case of tuberculosis in Michigan. BMC Public Health. 2019;19:1669. DOIPubMedGoogle Scholar
  32. US Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2021. 2022 [cited 2023 Nov 28]. https://www.cdc.gov/tb/statistics/reports/2021/table2.htm
  33. Ritz  S. Cash DH. Republic of the Marshall Islands hybrid survey: final report. 2018 [cited 2023 Dec 5]. https://cdn.who.int/media/docs/default-source/ncds/ncd-surveillance/data-reporting/marshall-islands/rmi-report-12_july_2018.pdf
  34. Riklon  S, Alik  W, Hixon  A, Palafox  NA. The “compact impact” in Hawaii: focus on health care. Hawaii Med J. 2010;69(Suppl 3):7–12.PubMedGoogle Scholar
  35. McElfish  PA, Post  J, Rowland  B. A social ecological and community-engaged perspective for addressing health disparities among Marshallese in Arkansas. Int J Nurs Clin Pract. 2016;3:3. DOIGoogle Scholar
  36. Rothfeldt  LL, Patil  N, Haselow  DT, Williams  SH, Wheeler  JG, Mukasa  LN. Notes from the field: cluster of tuberculosis cases among Marshallese persons residing in Arkansas—2014–2015. MMWR Morb Mortal Wkly Rep. 2016;65:882–3. DOIPubMedGoogle Scholar
  37. Pareek  M, Greenaway  C, Noori  T, Munoz  J, Zenner  D. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 2016;14:48. DOIPubMedGoogle Scholar
  38. Swaminathan  S, Rekha  B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis. 2010;50(Suppl 3):S184–94. DOIPubMedGoogle Scholar
  39. Ki  HP, Shingadia  D. Tuberculosis in children. Paediatrics Child Health (United Kingdom). 2017;27:109–15. DOIPubMedGoogle Scholar
  40. Labuda  SM, McDaniel  CJ, Talwar  A, Braumuller  A, Parker  S, McGaha  S, et al. Tuberculosis outbreak associated with delayed diagnosis and long infectious periods in rural Arkansas, 2010–2018. Public Health Rep. 2022;137:94–101. DOIPubMedGoogle Scholar
  41. Caraux-Paz  P, Diamantis  S, de Wazières  B, Gallien  S. Tuberculosis in the Elderly. J Clin Med. 2021;10:5888. DOIPubMedGoogle Scholar
  42. Yuen  CM, Kammerer  JS, Marks  K, Navin  TR, France  AM. Recent transmission of tuberculosis—United States, 2011–2014. PLoS One. 2016;11:e0153728. DOIPubMedGoogle Scholar
  43. Migliori  GB, Nardell  E, Yedilbayev  A, D’Ambrosio  L, Centis  R, Tadolini  M, et al. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. Eur Respir J. 2019;53:1900391. DOIPubMedGoogle Scholar
  44. Tedla  K, Medhin  G, Berhe  G, Mulugeta  A, Berhe  N. Delay in treatment initiation and its association with clinical severity and infectiousness among new adult pulmonary tuberculosis patients in Tigray, northern Ethiopia. BMC Infect Dis. 2020;20:456. DOIPubMedGoogle Scholar
  45. Mbuh  TP, Ane-Anyangwe  I, Adeline  W, Thumamo Pokam  BD, Meriki  HD, Mbacham  WF. Bacteriologically confirmed extra pulmonary tuberculosis and treatment outcome of patients consulted and treated under program conditions in the littoral region of Cameroon. BMC Pulm Med. 2019;19:17. DOIPubMedGoogle Scholar
  46. Yang  Z, Kong  Y, Wilson  F, Foxman  B, Fowler  AH, Marrs  CF, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis. 2004;38:199–205. DOIPubMedGoogle Scholar
  47. Office of Minority Health and Health Disparities and Epidemiological Branch. Disparities in diabetes mellitus mortality among Blacks in Arkansas. 2018 [cited 2023 Dec 5]. https://www.healthy.arkansas.gov/images/uploads/pdf/2018_Diabetes_Mortality_Disparity_Fact_Sheet.pdf
  48. World Health Organization. Framework for collaborative action on tuberculosis and comorbidities. Geneva: The Organization; 2022.
  49. Raz  KM, Talarico  S, Althomsons  SP, Kammerer  JS, Cowan  LS, Haddad  MB, et al. Molecular surveillance for large outbreaks of tuberculosis in the United States, 2014-2018. Tuberculosis (Edinb). 2022;136:102232. DOIPubMedGoogle Scholar

Top

Tables

Top

Cite This Article

DOI: 10.3201/eid3001.230778

Original Publication Date: December 13, 2023

Table of Contents – Volume 30, Number 1—January 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Zhenhua Yang, Epidemiology Department, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48105, USA

Send To

10000 character(s) remaining.

Top

Page created: November 30, 2023
Page updated: December 20, 2023
Page reviewed: December 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external